Examples of using Bleeding events in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Serious bleeding events during the infusion period.
The most serious adverse reactions were hypotension, bleeding events, and bronchospasm.
Serious bleeding events during the infusion period.
Cerebral haemorrhage andgastrointestinal haemorrhage were the most commonly reported serious bleeding events.
Serious bleeding events during the 28-day study period.
There are four different pulse adjustments inorder to optimize the function of the aorta valve and reduce chronic bleeding events.
Overall outcome of bleeding events in the PEGASUS study are shown in Table 3.
From those subjects, 8(38%) experiencedat least one bleeding during the 14 day-prophylaxis, while they had no bleeding events during once weekly prophylaxis.
Table 7: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study.
In the paediatric prevention study at25 mg/kg/day there was an increased incidence of any bleeding events in the defibrotide group compared with the treatment group.
Table 6: Bleeding Events in ENGAGE AF-TIMI 48 Study- Safety Analysis On-Treatment.
The second study involved 32 patients aged 12 years and above who were given Nuwiq to prevent andtreat bleeding events as well as to prevent bleeding during surgery.
The incidence of serious bleeding events was higher in patients with AP-CML, BP-CML and Ph+ ALL.
Besides detailed characterization of these mechanisms in patients with congenital hemophilia, findings will be correlated with clinically relevant endpoints such as the severity andfrequency of bleeding events and the prevalence of hemophilic arthropathy.
All clinically significant(≥ grade 3) bleeding events occurred at platelet counts< 30 x 109/ l.
Bleeding events associated to thrombocytopenia occurred in< 1% of patients treated with the monotherapy regimen.
The incidence of severe or life-threatening bleeding events with eptifibatide was common(> 1/ 100,< 1/ 10); 1.9% vs 1.1% with placebo.
In addition, the MVAD System incorporates a pulsatility algorithm called the qPulse™ Cycle that allows physicians to customize the device for each patient, providing four pulsesettings designed to enhance aortic valve function and reduce chronic bleeding events.
The frequency of bleeding events did not differ between iloprost and placebo-treated patients.
Infrequent bleeding events or elevations in the International Normalised Ratio(INR) have been reported in some patients taking warfarin while on Nexavar therapy.
During the infusion period in PROWESS and ENHANCE the incidence of serious bleeding events with Xigris was numerically higher in patients with recent[within 30 days] surgery than in patients without surgery PROWESS.
Bleeding events included serious bleeding events, bleeding events assessed as possibly study-drug related by the investigator, bleeding events associated with the need for a red blood cell transfusion, and bleeding events that led to permanent discontinuation of the study drug.
The following table lists the percent of patients in PROWESS andENHANCE experiencing serious bleeding events by site of haemorrhage during the study drug infusion period defined as the duration of infusion plus the next full calendar day following the end of the infusion.
There were few fatal bleeding events in the study, 11(0.3%) for ticagrelor 60 mg and 12(0.3%) for ASA therapy alone.
During the infusion period in PROWESS and ENHANCE the incidence of serious bleeding events with Xigris was numerically higher in patients with recent[within 30 days] surgery than in patients without surgery PROWESS: 3.3% vs 2.0%; ENHANCE: 5.0% vs 3.1% respectively.
In the ADDRESS trial, serious bleeding events included any fatal bleed, any life-threatening bleed, any CNS bleed, or any bleeding event assessed as serious by the investigator.
The incidence of serious bleeding events in the PROWESS and ENHANCE studies is provided below.
The incidence of non-major bleeding events and procedure-attributable events was low for both treatment arms.
In the placebo-controlled ADDRESS study, the incidence of serious bleeding events during the 28-day study period was 51(3.9%) and 28(2.2%) in drotrecogin alfa(activated)-treated and placebo-treated patients, respectively p=0.01.